GH Research PLC (GHRS)
$20.02-5.16%Close
SELLCRISIS · day 13
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.4B
- Beta
- 1.33
- P/E (TTM)
- -21.52
- Short % float
- 3.47%
- Days to cover
- 5.0
- SI change
- -34.8%
- 1W
- -9.70%
- 1M
- -26.40%
- vs SPY 1W
- -10.12%
- vs SPY 1M
- -28.46%
Industry peers
FMP comparable companies · ranked by market cap
- PVLASELLPalvella Therapeutics, Inc.$1.9BRECOVERYQ 14$132.16-3.16%
- NBTXSELLNanobiotix S.A.$1.3BCRISISQ 17$25.10-1.18%
- TYRASELLTyra Biosciences, Inc.$1.2BCRISISQ 5$20.93-1.71%
- SVRASELLSavara Inc.$980MRECOVERYQ 11$4.78-1.63%
- KURASELLKura Oncology, Inc.$943MBEARQ 12$10.62-1.89%
- ABUSSELLArbutus Biopharma Corp$923MCRISISQ 13$4.67-1.66%
- PROKSELLProKidney Corp.$531MRECOVERYQ 1$1.58-4.02%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on GHRS?
- LOPJLB’s latest quantitative signal on GH Research PLC (GHRS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is GHRS in?
- GH Research PLC (GHRS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does GH Research PLC (GHRS) do?
- GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candida…